Capabilities
The Hubs are prioritising the manufacture of lentivirus and adeno-associated virus (AAV), as these were identified as key needs of the academic gene therapies community.
The network will host scalable platforms that offer a range of batch sizes for academic early-phase clinical trials. Sites are expected to be available for manufacture from early 2023.
Please get in touch with us to discuss your needs.